The Neutrophil Respiratory Burst and Bacterial Digestion in Crohn's Disease

Department of Molecular Medicine, University College London, WC1E 6JJ, London, UK.
Digestive Diseases and Sciences (Impact Factor: 2.26). 10/2010; 56(5):1482-8. DOI: 10.1007/s10620-010-1426-8
Source: PubMed

ABSTRACT Neutrophils are a key part of the innate immune defence against microbes, using the respiratory burst (RB) to optimise killing and digestion. Previous studies of the neutrophil RB in Crohn's disease (CD) have yielded conflicting results.
Superoxide production in response to phorbol-myristyl acetate (PMA) was measured in neutrophils from 100 patients with CD compared to 50 healthy controls (HCs) and 50 patients with ulcerative colitis (UC). A further 22 CD and 10 HCs were studied using f-Met-Leu-Phe (fMLP), and digestion of E. coli by neutrophils was also evaluated.
The mean ± SEM PMA-stimulated RB (nmol O(2)/10(6) cells/min) was 10.86 ± 0.26 in HCs, 9.76 ± 0.23 in CD (P=0.02) and 10.04 ± 0.28 in UC (P=0.09 vs HC and 0.47 vs CD). No significant effect of age, gender or medication was observed. The RB in three patients with presumed CD was found to be in the range expected in patients with inherited neutrophil disorders. Stimulation with fMLP was calcium dependent and attenuated in patients on 5-ASA. Digestion of E. coli by neutrophils was not different in HC vs CD (21.6 vs 20.53%, P=0.60).
The significant reduction in neutrophil RB in CD does not appear to result in defective bacterial digestion and is therefore unlikely play a major role in pathogenesis. Three patients in this cohort of patients with presumed idiopathic CD were found to have a profound defect of the neutrophil RB. A high index of suspicion for such patients is prudent, as their prognosis can be improved by altering or augmenting the conventional treatment regimens employed for CD.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Significance: New insights into the role of reactive oxygen species (ROS) show that activators of the phagocyte NADPH oxidase (NOX2) complex have the potential to be therapeutic in autoimmune and inflammatory conditions. It is however essential to elucidate the consequence of targeting the NOX2 complex, as it might lead to different outcomes depending both on disease context as well as specificity, dose and timing of ROS production. Recent advances: Increasing evidence is suggesting that the role of the NOX2 complex is far more complex than previously anticipated. In addition to the well described antimicrobial response, ROS also have immune and inflammatory regulatory effects. Compounds increasing NOX2 dependent ROS production have been shown to be effective both in preventing and treating inflammatory manifestations in animal models of autoimmune diseases. Together, these results suggest the possibility of activating the NOX2 complex for treatment of autoimmune inflammatory diseases while restoring and maintaining a balanced ROS regulation. Critical issues: The complexity of the NOX system and the derived ROS is important and must be considered when designing programs for development of NOX2 activating drugs, as well as for validation of selected hits, in order to successfully identify substances effective in treating inflammatory and autoimmune conditions. In addition, it is important to consider the complex downstream immunological effects and safety for drugs that increase production of ROS. Future Directions: There is a strong potential for development of ROS inducing drugs, targeting the NOX2 complex, that are effective and safe, for treatment of inflammatory autoimmune disorders.
    Antioxidants & Redox Signaling 12/2013; DOI:10.1089/ars.2013.5788 · 8.20 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The role of the innate immunity in the pathogenesis of Crohn's disease (CD), an inflammatory bowel disease, is a subject of increasing interest. Neutrophils (PMN) are key members of the innate immune system which migrate to sites of bacterial infection and initiate the defence against microbes by producing reactive oxygen species (ROS), before undergoing apoptosis. It is believed that impaired innate immune responses contribute to CD, but it is as yet unclear whether intrinsic defects in PMN signal transduction and corresponding function are present in patients with quiescent disease. We isolated peripheral blood PMN from CD patients in remission and healthy controls (HC), and characterised migration, bacterial uptake and killing, ROS production and cell death signalling. Whereas IL8-induced migration and signalling were normal in CD, trans-epithelial migration was significantly impaired. Uptake and killing of E. coli were normal. However, an increased ROS production was observed in CD PMN after stimulation with the bacterial peptide analogue fMLP, which was mirrored by an increased fMLP-triggered ERK and AKT signal activation. Interestingly, cleavage of caspase-3 and caspase-8 during GMCSF-induced rescue from cell-death was decreased in CD neutrophils, but a reduced survival signal emanating from STAT3 and AKT pathways was concomitantly observed, resulting in a similar percentage of end stage apoptotic PMN in CD patients and HC. In toto, these data show a disturbed signal transduction activation and functionality in peripheral blood PMN from patients with quiescent CD, which point toward an intrinsic defect in innate immunity in these patients.
    PLoS ONE 12/2013; 8(12):e84521. DOI:10.1371/journal.pone.0084521 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: & Aims: The colitis observed in patients with very early onset inflammatory bowel disease (VEOIBD, defined as onset of disease < 6 years of age), often resembles that of chronic granulomatous disease (CGD) in extent and features of colonic inflammation observed by endoscopy and histology. CGD is a severe immunodeficiency caused by defects in the genes that encode components of the NADPH oxidase complex. We investigated whether variants in genes that encode NADPH oxidase components affect susceptibility to VEOIBD using independent approaches.
    Gastroenterology 06/2014; 147(3). DOI:10.1053/j.gastro.2014.06.005 · 12.82 Impact Factor